To validate the alteration of immune features in the enhanced therapeutic efficacy of HIF1 LNA, we investigated the tumor‐immune microenvironment of B16F10 tumor‐bearing mice treated with HIF1 LNA and ICB in combination or alone. Here, HIF1A is linked to neoplasm.